Lung transplantation is the only effective treatment for final stage pneumonopathy. However, bronchitis obliterans, as the main of complication, can prevent the long term survival after lung transplantation. Tracheal epithelium cell is the main target organ of the tardive reject reaction. This paper briefly explains the immunologic mechanism regarding the development of bronchitis obliterans, and the role of tracheal epithelium cell in the study, with aim of exploring the initial relationship between tracheal epithelium cell and bronchitis obliterans, and to find a method to solve the long-term survival of lung transplantation.

Objective To study the relationship between helicobocter pylori(Hp)infection and iron deficiency anemia(IDA)in children.Methods Children who had upper digestive symptom were had gastroscopy examination and Hp test.According to the examination results,all the patients were divi-ded into 2 groups,the observation group and the control group.All patients were detected blood routine,serum iron(SI),serum ftrritin(SF)and total iron-binding capacity(TIBC).Results The IDA morbidity was 52.27%(23/44 cases)in obsorvation group and 17.39%(8/46 cases)in control group,there was obvious difference between two groups(?2=12.12 P

OBJECTIVE:To observe the therapeutic effect of compound glycyrrhizin on ulcerative colitis.METHODS:165cases of ulcerative colitis were divided into two groups:trial group(compound glycyrrhizin)and control group(sulfasalazine). The clinical effects were compared between two groups.RESULTS:The total effective rates were92.38%in trial group and65%in control group(P

Objective To evaluate the efficacy in aromatase inhibitors and tamoxifen on Luminal postmenopausal breast neoplasms.Methods PubMED,Science Direct,EBSCO Host,EMbase,The Cochrane Library,CNKI,CECDB and CQVIP were retrieved,the evaluation methodology included.The quality of the included studies and extracted data should be researched rigorously.Review Manager 5.0 software was used to evaluate the quality standards of randomized clinical trial (RCT).Results Twelve RCT were selected,included 2634 patients,1354 cases of treatment group (use aromatase inhibitors),1280cases of control group (use tamoxifen).The results of the evaluation of the system:compared to control group,treatment group significantly improved disease-free survival in 1 year (RR =1.10,95％ CI 1.01-1.19),disease-free survival in 3 years (RR =1.09,95％ CI 1.05-1.13),the overall efficiency in 1 year (RR =1.21,95％ CI 1.12-1.30),furthermore treatment group significantly reduced the incidence of cardiovascular diseases in 3 years (RR =0.47,95％ CI 0.27-0.83),but there was no significant difference in the incidence of bone and joint disease in 3 years between the 2 groups (RR =0.99,95％ CI 0.61-1.61).Conclusion Compared to tamoxifen,the efficacy of aromatase inhibitors is excellent in treatment of Luminal postmenopausal breast neoplasms,it is worth promoting.

Objective To investigate the levels of interleukin 1? (IL 1?) and tumor necrosis factor ? (TNF ?) in both serum and CSF in patients with Alzheimer's disease Methods Eleven patients with Alzheimer's disease,13 patients with vascular dementia (VD) and 13 healthy controls were analyzed by using commercial ELISA kits Results The average serum level of IL 1? was found higher in AD patients(60 13?17 81 pg/ml) than in VD patients(38 51?14 39 pg/ml) and in healthy controls(33 98?16 31 pg/ml)( P

Objective To compare the clinical efficacy and adverse effects of pegaspargase (PEGASP) and L-asparaginase (L-ASP) in the treatment of NK/T-cell lymphoma.Methods A retrospective analysis was conducted on the clinical data of 46 patients with NK/T-cell lymphoma in Department of Oncology of Hospital of Qingdao Commercial Staff from September 2009 to July 2015.There were 24 patients treated by PEG-ASP combined with GDP (gemcitabine + cisplatin + dexamethasone) as PEG-ASP group,and 22 patients treated by L-ASP combined with GDP as L-ASP group.The efficacy and adverse reactions were compared between the two groups.Results In the PEG-ASP group,there were 11 patients with complete remission,7 patients with partial remission,and the complete remission rate and objective response rate were 45.83％ and 75.00％.In the L-ASP group,there were 9 patients with complete remission,6 patients with partial remission,and the complete remission rate and objective response rate were 40.91％ and 68.18％.There was no significant difference between the two groups in objective response rate (x2 =0.263,P =0.608).Adverse effects such as myelosuppression (25.00％ vs.22.73％,x2 =0.033,P =0.857),coagulopathy (8.33％ vs.9.10％,x2=0.008,P =0.927),liver and renal dysfunction (8.33％ vs.18.18％,x2 =0.982,P=0.322),gastrointestinal reaction (41.67％ vs.40.91％,x2 =0.003,P =0.958) were similar in the PEGASP group and L-ASP group.But the risk of allergic reaction incurred by PEG-ASP was much lower than L-ASP (4.17％ vs.36.36％),with a significant difference (x2 =7.561,P =0.006).Moreover,the PEGASP group had a shorter duration of hospitalization [(10.04 ± 1.63) d] than the L-ASP group [(13.09 ± 2.76)d],with a significant difference (t=-4.612,P=0.000).Conclusion The efficacy of PEG-ASP and L-ASP in the treatment of NK/T-cell lymphoma is similar,but the rate of allergic reaction of patients treated with PEG-ASP is significantly lower,and the hospitalization time is significantly shorter,which is worthy of further clinical application.

Objective To explore clinical effect of nedaplatin combined gemcitabine on chemotherapy of advanced non-small cell lung cancer (NSCLC),and to observe the prognosis and complications of these patients. Methods 106 patients with advanced NSCLC were selected,they were randomly divided into the treatment group and the control group with 53 cases each group,according to the single and double of order registration number.The con-trol group were given cisplatin combined gemcitabine chemotherapy,the treatment group were administrated nedaplatin combined gemcitabine chemotherapy,three weeks repeat.The treatment effect was estimated after two cycles of chemo-therapy,and progression-free survival ( PFS) ,patients quality of life with KPS after treatment,and the adverse reac-tions were assessed.Results The disease control rates (DCR) of the treatment group was 77.36% (41/53),the control group was 71.70%(38/53),there was no statistically significant difference (χ2 =2.46,P>0.05).PFS of the treatment group were (4.26 ±0.38) months,the control group was (3.72 ±0.30) months,there was no statisti-cally significant difference (t=2.94,P>0.05).KPS of the treatment group was (74.48 ±4.04)points,which was higher than (69.76 ±3.28)points of the control group,the difference was statistically significant (t =7.33,P<0.05).The total adverse reaction of the treatment group was 81.13%(43/53),which was lower than the control group 90.57%(48/53),the difference was statistically significant (χ2 =7.61,P<0.05).Conclusion There is preferably clinical effect of nedaplatin combined gemcitabine treatment of NSCLC,the adverse reactions was lower sig-nificantly,the patients prognosis is good,and which is worth clinical promotion.

Objective:To investigate the influence of type A behavior in the occurrence and development of chromic periodontitis and compare the differences among people with different behavior types in the occurrence and development of chronic periodontitis, and to explore the influence of psychological factors in the process of periodontitis.Methods:According the same standard,132 patients with periodontitis were selected as periodontitis group,and 126 patients without periodontitis were used as control group.OralSurveys Basic Methods proposed by WHO in 1987 and ReferenceStandard of Diagnosis and Treatment of Periodontitis made by AAP in 2000 were used to dignose the periodontitis.All subjects finished type A behavior and SCL-90 questionnaire (ZHANG Boyuan 1983,revision in 1985 ), their scores were recorded and the results were analyzed by t test. Results:The proportion of type A behavior in periodontits group (68.94%)was higher than that in control group (27.78%) (P<0.05)compared with type M and type B behavior.The scores of hostility (1.54±0.38),anxiety (1.47± 0.39),depression (1.41 ± 0.37),interpersonal sensitivity (1.23 ± 0.39),compulsive (1.72 ± 0.46),and somatizition (1.47 ± 0.38)were significantly higher than those in control group (1.32 ± 0.30, 1.29 ± 0.24, 1.25±0.23,1.04± 0.17,1.41 ± 0.35,1.25 ± 0.24).The calculus index (CI)of the people with type A behavior was higher than those of the people with other types of behavior (P<0.05).Conclusion:The people with tyep A behawior is easier to get periodontitis than other people.

Objective To evaluate the role of postoperative electron beam radiotherapy in the management of ke-loids. Methods Between January 2004 and December 2006,116 cases of keloids were treated with 6 MeV electron beam radiotherapy within 24 h after surgical resection of the keloids. All patients had received a total of 21 Gy in seven daily 3-Gy fractions. Treatment was started at the 24th h after surgery. Patients were followed up and the information regarding treatment results, early and late radiation toxicity,and the satisfaction level by self-assessments was recorded. Results Recurrence occurred in 17 cases of keloids(14. 7%),and was correlated with site of the lesions(χ~2 =29. 91,P<0. 01). Most recurrences were observed at site of sternum (10/43) and shoulder (5/13 ). Keloid associated symptoms, e. g. itching and pain, were improved in 88. %%. For early toxicity outcomes, 100% had grade 1～2 skin erythema,7. 8% had wound delayed union,and 4. 3% had infection. For late toxicity outcomes, 30. 2% reported grade 1～2 hyperpigmentation, 11. 2% grade 1～2 hypopigmentation, and 5. 2% grade 1 telangiectasia. No severe complications or secondary malignancies were observed. 72. 4% patients described the results of treatment as excellent or good,and 15. 5% patients were not satisfied with the treatment results. Conclusion Postoperative electron radiotherapy is well tolerated and effective in preventing keloid recurrence.

Bone marrow stromal antigen 2 (BST-2) is a kind of host restriction factor. Since it was discovered to be responsible for the defect in virion release of HIV-1 mutants lacking the accessory gene vpu in 2008, it was thought to mainly restrict the viruses by directly tethering viral particles at the plasma membrane. Recent reports suggest that BST-2 also can inhibit the the release of HBV particles, which are budding in the intracellular vesicles, expanding the antiviral spectrum of BST-2. Futhermore, the machanism that BST-2 used to restrict HBV release in multivesicular bodies (MVBs) is similar to that used to restrict HIV at the plasma membrane. However, HBV have evolved strategies to antagonize the antiviral action of BST-2. There are two different opinions about the antagonist. One is HBV inactivated BST-2 by HBx requiring a hepatocyte-specific environment. Another thought envelope protein HBs counteract the antiviral action of BST-2. In this review, we focus on the current advances in the anti-HBV activity of BST-2.
Animals ; Antigens, CD ; genetics ; immunology ; GPI-Linked Proteins ; genetics ; immunology ; Hepatitis B ; genetics ; immunology ; virology ; Hepatitis B virus ; genetics ; physiology ; Host-Pathogen Interactions ; Humans ; Virus Release